Latest Expert Exchange Queries

GST Demo Service software link: https://ims.go2customer.com
Username: demouser Password: demopass
Get your inventory and invoicing software GST Ready from Binarysoft info@binarysoft.com
sitemapHome | Registration | Job Portal for CA's | Expert Exchange | Currency Converter | Post Matrimonial Ads | Post Property Ads
 
 
News shortcuts: From the Courts | News Headlines | VAT (Value Added Tax) | Placements & Empanelment | Various Acts & Rules | Latest Circulars | New Forms | Forex | Auditing | Direct Tax | Customs and Excise | ICAI | Corporate Law | Markets | Students | General | Mergers and Acquisitions | Continuing Prof. Edu. | Budget Extravaganza | Transfer Pricing | GST - Goods and Services Tax
 
 
 
 
Popular Search: ICAI offer Get Windows 7,Office 2010 in Rs.799 Taxes :: Central Excise rule to resale the machines to a new company :: cpt :: due date for vat payment :: VAT Audit :: VAT RATES :: ARTICLES ON INPUT TAX CREDIT IN VAT :: form 3cd :: TDS :: ACCOUNTING STANDARD :: articles on VAT and GST in India :: TAX RATES - GOODS TAXABLE @ 4% :: list of goods taxed at 4% :: empanelment :: ACCOUNTING STANDARDS
 
 
« Mergers and Acquisitions »
 Global Microdissection Market - Mergers and Acquisitions Becomes a Key Strategy
 How India's Bankruptcy Law Redo May Spur M&A Heyday
 Top 3 Procurement Mergers and Acquisitions of 2017 (and 2018, So Far)
 What is in store for mergers and acquisitions?
 Mergers and acquisitions a key factor in increasing the number of B.C. employees at top security firms
 Merger & Acquisition deals up 10 pct in 2017, but value declines
 OMA Emirates scouting for acquisitions in India’s fintech space
 India to see healthy M&A activity, says EY
 Digital payments gateway PayU eyes acquisitions to enter lending segment
 Top 5 mergers and acquisitions of 2017 in India
 Deals of the day-Mergers and acquisitions Jan 16, 2018

M&A deals to expand market presence
July, 15th 2009

Lifeline Industries Ltd engaged in the manufacture of active pharmaceutical ingredients (APIs) and intermediates is aggressively scouting for promising mergers and acquisitions (M&A) as part of its inorganic growth strategy. It is now looking at units which can fit into its line of business both in India and abroad.

Viewing opportunities in the market, the company under its organic growth efforts has also invested $50 million and is currently in the process of modernizing units at Bidar in north Karnataka, Solapur and Tarapur in Maharashtra to generate more capacities and also seek US FDA certification for its Mahad plant.

Since Lifeline has made substantial investments in the last couple of years, it is now focused on a fast paced growth plan. M&As are done to synergize and increase scale of operation. Efforts are on to tap Africa, CIS, Latin America, Russia, Brazil which have good opportunity for growth. "We are gearing up for growth both through organic and inorganic paths. This is through constant expansion of capacities to offer new products besides scout for potential M&A deals", Nikunj Kanakia, chairman & managing director, Lifeline Industries told Pharmabiz.

The company will go ahead with its aggressive growth strategy this fiscal, despite the economic slowdown. There have been positive and negative fallouts of the global slow down. On the positive side, most pharma and healthcare companies are looking at low cost destinations to manufacture their products. India still remains an attractive destination for most pharma companies globally. Due to recession, the country is the most preferred market for setting up operations. On the negative side, payment cycles have gone up leading to liquidity issues for quite a few companies. But the economic slow down has given Lifeline an opportunity to focus more on its operational efficiencies, he added.

Prospects of API and intermediates' are powered by the growth in generics and demand from regulated market for outsourcing. The demand is expected to grow at CAGR of 15-18 per cent with market size between $13billion and $15 billion.

As far as growth opportunities in India are concerned, focus will be on generics market. The recent trends are drugs going off patent and rise in Contract Research and Manufacturing Services (CRAMS) due to cost advantage.

In the last decade, the market has gone through a sea of change and India is today the third largest API manufacturer in the world with the highest number of US FDA approved plants.

Now there is a reverse trend as India has emerged as an important global player from being a mere importer of API. Today, the number of Drug Master Files filed by companies here are on the rise. This change is attributed to the core competency of Indian players giving importance to R&D and upgrading the plants to international standards. This will see India's API sales in overseas markets expected to be grow higher than domestic sales.

 
 
Home | About Us | Terms and Conditions | Contact Us
Copyright 2018 CAinINDIA All Right Reserved.
Designed and Developed by Binarysoft Technologies Pvt. Ltd.
Binarysoft Technologies - Contact Us

Transfer Pricing | International Taxation | Business Consulting | Corporate Compliance and Consulting | Assurance and Risk Advisory | Indirect Taxes | Direct Taxes | Transaction Advisory | Regular Compliance and Reporting | Tax Assessments | International Taxation Advisory | Capital Structuring | Withholding tax advisory | Expatriate Tax Reporting | Litigation | Badges | Club Badges | Seals | Military Insignias | Emblems | Family Crest | Software Development India | Software Development Company | SEO Company | Web Application Development | MLM Software | MLM Solutions